Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BX-U001 in refractory rheumatoid arthritis
NCT03828344Phase 1Not yet recruiting
- Sponsor
- Baylx
- Start
- Dec 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, randomised, double-blind trial of BX-U001 in rheumatoid arthritis (RA), sponsored by Baylx. Primary endpoint: Frequency of Adverse Events and Serious Adverse Events at 52 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BX-U001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03828344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828344.